WO1992004013A1 - Multiparticulate sustained release matrix system - Google Patents
Multiparticulate sustained release matrix system Download PDFInfo
- Publication number
- WO1992004013A1 WO1992004013A1 PCT/EP1991/001562 EP9101562W WO9204013A1 WO 1992004013 A1 WO1992004013 A1 WO 1992004013A1 EP 9101562 W EP9101562 W EP 9101562W WO 9204013 A1 WO9204013 A1 WO 9204013A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- xanthan gum
- minitablets
- dosage form
- matrix
- pharmaceutical dosage
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Definitions
- the present invention relates to an oral dosage system of pharmacologically active substances consisting of different small tablets, each having a prolonged and controlled release, filled into hard gelatin capsules.
- Hydrophilic matrix tablets consist fundamentally of a homogeneous mixture of the active medicament and one or more polymers which dissolve slowly in water.
- US Patent No. 4,259,341 to Lowey US Patent No. 3,870,790 to Lowey et al and US Patent No. 4,226,849 to Schor and US Patent No 4,357,469 to Schor concern the preparation of tablets with a hydrophilic matrix of hydroxypropylmethylcellulose, alone cr mixed with other cellulose derivatives, which have undergone treatments, that is forced dehydration, humidification, hydrolysis aned oxidation.
- hydroxypropylmethylcellulose to prepare controlled-release hydrophilic matrix and examines the influence of various parameters characteristic of hydroxypropylmethylcellulose, such as molecular weight, degree of substitution; granulometric distribution, hydration velocity, on the release of the active medicamen .
- the EURO PCT Patent Application EP 261,213 C O 87/5212 discloses hydrophilic matrix tablets in which the matrix consists of Xanthan Gum alone or in a mixtrue (50% maximum) with hydrophilic cellulose polymers such as hydroxypropylmethylcellulose and hydroxypropylcellulose.
- the following advantages are obtained: a more reproducible release; an improved gastro-intestinal tolerance; a more uniform concentration of the active medicament in the blood without "peaks" , which often cause negative side effects, and therefore a greater acceptability for the patient.
- the methods of producing the small sustained-release spheres are very long and complex and therefore expensive.
- the dimensions of the spherules are not equal, but since they are distributed in a large range the release of single spherules, after coating with the delaying membrane, will not be homogeneous either.
- the second is due to the fact that the minitablets form gelatinous layer and stick together on contact with the gastro-intestinal juices.
- the colvmer constituent of the minitablet matrix hydrates and forms a gelatinous layer.
- the single units stick together giving rise to a single mass which proceeds along the gastro-intestinal tract like a single large tablet so cancelling out the desired advantages of the multiparticulate form.
- the object of the present invention are small hydrophilic matrix tablets which are not only slow-releasing but also do not aggregate when hydratec.
- these minitabs permit the administration of an economical controlled-release multiparticulate form and the units remain in single entities along the gastro-intestinal tract .
- pharmaceutical dosage form comprising a hard gelatin capsule containing a multiplicity of minitablets providing prolonged and regular release of the active ingredient, said tablets comprising one or more active medicaments contained within a matrix which provides a sustained release effect, the matrix consisting essentially of xanthan gum or a mixture of xanthan gum and one or more natural or synthetic polymers, which hydrate and dissolve in water or gastric juices.
- the present invention concerns the preparation of controlled-release minitablets obtained by compression of an active medicament, xanthan gum and possible other inert excipients commonly utilized for the production of tablets such as lubricants, fillers and flowing agents.
- the xanthan gum is a natural polymer with a high molecular weight or more specifically a biopolysaccharide , fermentation product of the microorguni ⁇ iu Xa.ithou-onas C ⁇ mpe-ctris.
- the structure, the molecular weight, and the dissolution properties of this polymer are constant and reproducible in strictly controlled working conditions.
- Xanthan gum is used in numerous fields including the pharmaceutical, cosmetic and food industries. in these cases the thickening and stabilizing properties of emulsions or suspensions given by xanthan gum in solution are made use of .
- the matrix can consist of xanthan gum only or as a mixture of xanthan gum always being 50% or higher with respect to the polymer.
- the delaying matrix is mixed in suitable apparatus with the desired active medicament or even medicaments to be administered in a sustained-release formulation.
- active medicaments we cite as an illustrative, but not restrictive, example adrenergicamines (ethylephrine , phenylephrine, phenylpropanolamine, d-pseudoephendrin) , antispasmodics (scopolamine, and other alkaloids of belladonna, papaverine and derivatives), antihistamines (broncopheniramine, chlorpheniramine , diphenylpiraline, dimenhydr(in)ate) , anorexics (norpsuedoephedrin, fentermine, diethylpropion, flenfuramine) , antiasthmatics (theophylline , salbutamol, terbutaline) , antianginous (isosorbide-5-mononitrate, isosorbide
- inert excipients commonly used by experts in the art may be present in the formulation, in order to improve its characteristics .
- lubricants for example in the preparation of minitablets, lubricants, inert excipients, etc. can be added to improve the flowability of the powder, the appearance, the precision of the dose.
- the quantity of matrix used to delay the release of the active medicament can vary widely depending on whether the formulation consists only of active medicament and matrix or if there are other excipients present, in various quantities according to whether the active medicament is very or not very soluble and whether the dose is high or low.
- the minitablets are produced using the usual tabletting machines as for example the Ronchi rotary type AM13 equipped with punches and matrices adapted in order to obtain minitablets with a diameter less than 4 mm and preferably between 2 - 2.5 mm.
- the invention also includes a method for the preparation of a pharmaceutical dosage form which method comprises mixing an active medicament with xanthan gum or a mixture of xanthan gum and one or more natural or synthetic polymers, which hydrate and dissolve in water or gastro-intestinal juices, forming the mixture into minitablets, filling the minitablets into hard gelatin capsules so that each capsule contains a multiplicity of minitablets, the xanthan gum or xantham gum mixture providing a matrix from which in use the active medicament has a prolonged and regular release .
- the mixture obtained from A) is compressed with a tablettin ⁇ machine, model Ronchi AM13 e ⁇ uipped with punchers (diameter 2 mm, bending radius 3 mm) giving minitablets with an average weight of 9.2 g and each containing 6 mg of ibuprofen.
- Each capsule contains 200 mg of ibuprofen.
- the minitablets were analysed with the rotating paddle method described in the current edition of the US Pharmacopoeia (USP) using 90C ml of artificial intestinal juice with pH 6.8 and a rotation speed of 50 rpm.
- the granules are dried at about 40 C for 12-15 hours in a circulating air oven and selected between 300 and 700 ⁇ m.
- the following materials are transferred in a double cone shaped laboratory mixer: granulated sodium diclofenac (300-700 ⁇ m) 800. Og xanthan gum 1140. Og silicon dioxide 20. Og magnesium stearate 40. Og mix for about 15 minutes.
- the mixture obtained from A) is compressed with a tabletting machine , model Ronchi AM13 equipped with punchers (diameter 2mm, bending radius 3mm) giving minitablets with an average weight of 7.7 mg and each containing 2.9 mg of diclofenac.
- type Snap Fit size 1,35 of the small tablets produced in B were introduced into each capsule with a suitable capsule filling machine •
- Each capsule contains 100 mg of sodium diclofenac.
- the minitablets were analysed with the rotating paddle mthod described in the current edition of the US Pharmacopoeia (USP) using 900 ml of artificial intestinal juice with pH 6.8 and a rotation speed of 50 rpm.
- type Coni Snap Fit size 0 ,45 of the small tablets produced in B were introduced into each capsule with a suitable filling machine.
- Each capsule contains 200 mg of theophylline.
- the minitablets were analyzed with the rotating paddle method described in the current edition of the US Pharmacopoeia (USP) using 900 ml of artificial intestinal juice with pH 7.5 and a rotation speed of 50 rpm.
- the minitablets were analyzed as described above using 900ml of artificial gastric juice with pH 1.2
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to an oral dosage system of pharmacologically active substances consisting of different small tablets, each having a prolonged and controlled release, filled into hard gelatin capsules. Specifically the small tablets have a hydrophilic matrix made of xanthan gum, alone or mixed with other hydrophilic polymers, by which the slow release of the drug along the gastro-intestinal tract is obtained.
Description
MULTIPARTICULATE SUSTAINED RELEASE MATRIX SYSTEM
The present invention relates to an oral dosage system of pharmacologically active substances consisting of different small tablets, each having a prolonged and controlled release, filled into hard gelatin capsules.
Hydrophilic matrix tablets consist fundamentally of a homogeneous mixture of the active medicament and one or more polymers which dissolve slowly in water.
For Example:
US Patent No. 4,259,341 to Lowey , US Patent No. 3,870,790 to Lowey et al and US Patent No. 4,226,849 to Schor and US Patent No 4,357,469 to Schor concern the preparation of tablets with a hydrophilic matrix of hydroxypropylmethylcellulose, alone cr mixed with other cellulose derivatives, which have undergone treatments, that is forced dehydration, humidification, hydrolysis aned oxidation.
US Patent No. 4,369,172 and No. 4,389,393 to Schor et al which concern the use of one or more types and well-defined quantities of hydroxypropylcel1ulose alone or mixed with methylcellulose and/or sodium carboxymethylcellulose.
US Patent No. 4,167,446 and No. 4,126,672 to Sheth et al which concern the use of hydroxypropylmethylcellulose for the preparation of tablets and especially hydrophilic matrix capsules in such a form that they float in the digestive juices of the stomach.
The article entitled "A Review of Cellulose Ethers in Hydrophylic Matrices for Oral Controlled-release Dosage Forms" by D.A. Alderman, published in Int.J.Pharm.Tech and Prod.Mfr. , 5 (3) 1-9, 1984, describes extensively the use of hydroxypropylmethylcellulose to prepare controlled-release hydrophilic matrix and examines the influence of various parameters characteristic of hydroxypropylmethylcellulose, such as molecular weight, degree of substitution; granulometric distribution, hydration velocity, on the release of the active medicamen .
The EURO PCT Patent Application EP 261,213 C O 87/5212) (corresponding to Italian Patent application No. 19 675 A/86) discloses hydrophilic matrix tablets in which the matrix consists of Xanthan Gum alone or in a mixtrue (50% maximum) with hydrophilic cellulose polymers such as hydroxypropylmethylcellulose and hydroxypropylcellulose.
The advantage of these large matrix polymers is their low cost, but they have various disadvantages since they tend to adhere to the stomach and intestinal walls, causing irritation of the mucosa and irregular absorption of the active medicament.
These disadvantages are overcome by the multiparticulate form as spherules composed of active medicament coated with a polymeric membrane which delays the dissolution. These spherules of controlled-release medicament are filled into hard gelatin capsules which, when ingested, dissolve to release the tens and sometimes hundreds of spherules which disperse along the gastro-intestinal tract, thus
avoiding a high local concentration of the active medicament.
With this multiparticulate form the following advantages are obtained: a more reproducible release; an improved gastro-intestinal tolerance; a more uniform concentration of the active medicament in the blood without "peaks" , which often cause negative side effects, and therefore a greater acceptability for the patient. However, the methods of producing the small sustained-release spheres are very long and complex and therefore expensive. In addition the dimensions of the spherules are not equal, but since they are distributed in a large range the release of single spherules, after coating with the delaying membrane, will not be homogeneous either.
These disadvantages can be overcome by preparing the tablets with a matrix of small dimensions (also called minitablets* to fill hard gelatin capsules, sc obtaining a multiparticulate form.
The production of small hydrophilic matrix tablets however is not very easy and presents two main problems. The first is due to the fact that the small dimensions, the permeability and the solubility of the polymers utilized for the hydrophilic matrix preparation do not permit to delay sufficiently the dissolution of the active medicament.
The second is due to the fact that the minitablets form gelatinous layer and stick together on contact with the gastro-intestinal juices. In fact when the gelatin capsule is ingested and dissolves, the colvmer
constituent of the minitablet matrix hydrates and forms a gelatinous layer. The single units stick together giving rise to a single mass which proceeds along the gastro-intestinal tract like a single large tablet so cancelling out the desired advantages of the multiparticulate form.
G.B. Patent No 2,176,999 managed to get around the first of these problems by the addition of an ionic substance to the minitablet formulation, in addition to the hydroxylalkylcellulose ethers , with a large opposite to that of the active medicament, preferably an ionic exchange resin, with the function of delaying the release of the active medicament as specified in the text of the patent and as known (see for example European Patent Appln. 0294103 A of Muneo Nonomura et al) . *
The object of the present invention are small hydrophilic matrix tablets which are not only slow-releasing but also do not aggregate when hydratec.
In fact we have discovered, very surprisingly, that if natural xanthan gum is used as the hydrophilic matrix, minitablets with the above-mentioned characteristics are obtained.
Once put in the capsule, these minitabs permit the administration of an economical controlled-release multiparticulate form and the units remain in single entities along the gastro-intestinal tract .
According to the invention there is provided a
- _- -
pharmaceutical dosage form comprising a hard gelatin capsule containing a multiplicity of minitablets providing prolonged and regular release of the active ingredient, said tablets comprising one or more active medicaments contained within a matrix which provides a sustained release effect, the matrix consisting essentially of xanthan gum or a mixture of xanthan gum and one or more natural or synthetic polymers, which hydrate and dissolve in water or gastric juices.
The present invention concerns the preparation of controlled-release minitablets obtained by compression of an active medicament, xanthan gum and possible other inert excipients commonly utilized for the production of tablets such as lubricants, fillers and flowing agents.
We have found, very surprisingly, that if xanthan gum is used as a hydrophilic matrix, the release of the active medicament is slowed down. Moreover when the polymer is hydrated giving rise to the formation of a superficial gelatinous layer the single units do not stick together therefore maintaining all the advantages of multiparticulate form.
The xanthan gum is a natural polymer with a high molecular weight or more specifically a biopolysaccharide , fermentation product of the microorguni≤iu Xa.ithou-onas Cάmpe-ctris. The structure, the molecular weight, and the dissolution properties of this polymer are constant and reproducible in strictly controlled working conditions.
Xanthan gum is used in numerous fields including the pharmaceutical, cosmetic and food industries. in these
cases the thickening and stabilizing properties of emulsions or suspensions given by xanthan gum in solution are made use of .
With the present invention we found that it is possible to make use of xanthan gum's properties also in solid forms of medicament, using it for the preparation of the hydrophilic matrix in which xanthan gum has a retarding effect on the dissolution of the medicament.
The matrix can consist of xanthan gum only or as a mixture of xanthan gum always being 50% or higher with respect to the polymer.
The delaying matrix is mixed in suitable apparatus with the desired active medicament or even medicaments to be administered in a sustained-release formulation. Among the active medicaments we cite as an illustrative, but not restrictive, example adrenergicamines (ethylephrine , phenylephrine, phenylpropanolamine, d-pseudoephendrin) , antispasmodics (scopolamine, and other alkaloids of belladonna, papaverine and derivatives), antihistamines (broncopheniramine, chlorpheniramine , diphenylpiraline, dimenhydr(in)ate) , anorexics (norpsuedoephedrin, fentermine, diethylpropion, flenfuramine) , antiasthmatics (theophylline , salbutamol, terbutaline) , antianginous (isosorbide-5-mononitrate, isosorbide dinitrate, pentaerythritol tetranitrate, nitroglycerin, nifedipin, diltiazem) , anti-inflammatory and antipyretics (indomethacin, ibuprofen, ketoprofen, aspirin, paracetamol, phenacetin), antiphypertensives (nifedipin, idralazin, prazosin, verapamil), antidepressives (amitriptyline , lithium salts),
antitussive (destromethorphan, noscapine, codeine), gastroenteric (cimetidine, ranitidine, metoclopramide) antiarrhythmic (procainamide , lidocaine, flecainide, propafenone ) , analgesics (morphine), vitamins (ascorbic acid) and their salts used in the pharmaceutical field.
Apart from polymers and medicaments, inert excipients commonly used by experts in the art may be present in the formulation, in order to improve its characteristics .
For example in the preparation of minitablets, lubricants, inert excipients, etc. can be added to improve the flowability of the powder, the appearance, the precision of the dose.
The quantity of matrix used to delay the release of the active medicament can vary widely depending on whether the formulation consists only of active medicament and matrix or if there are other excipients present, in various quantities according to whether the active medicament is very or not very soluble and whether the dose is high or low.
The minitablets are produced using the usual tabletting machines as for example the Ronchi rotary type AM13 equipped with punches and matrices adapted in order to obtain minitablets with a diameter less than 4 mm and preferably between 2 - 2.5 mm.
The invention also includes a method for the preparation of a pharmaceutical dosage form which method comprises mixing an active medicament with xanthan gum or a mixture of xanthan gum and one or more
natural or synthetic polymers, which hydrate and dissolve in water or gastro-intestinal juices, forming the mixture into minitablets, filling the minitablets into hard gelatin capsules so that each capsule contains a multiplicity of minitablets, the xanthan gum or xantham gum mixture providing a matrix from which in use the active medicament has a prolonged and regular release .
The following examples which serve to better illustrate the invention must not be considered in any way as restrictive of the scope of the present invention and possible variations are obvious for experts in this field.
EXAMPLE 1
A) Preparation of the Mixture
Transfer the following raw materials, previously sieved through a 0.5 mm sieve, in a stainless steel laboratory cube mixer
ibuprofen 219.Og xanthan gum 45. Og cornstarch 12. Og glyceryl behenate 4.5g magnesium stearate 4.5g mix for about 15 minutes.
B) Preparation of the Minitablets
The mixture obtained from A) is compressed with a tablettinα machine, model Ronchi AM13 eσuipped with
punchers (diameter 2 mm, bending radius 3 mm) giving minitablets with an average weight of 9.2 g and each containing 6 mg of ibuprofen.
C) Preparation of the Final Pharmaceutical Form
Utilizing hard gelatin capsules, type Coni Snap Supro-A, 34 of the smail tablets produced in B were introduced into" each capsule with a suitable capsule filling machine.
Each capsule contains 200 mg of ibuprofen.
D) Analysis
The minitablets were analysed with the rotating paddle method described in the current edition of the US Pharmacopoeia (USP) using 90C ml of artificial intestinal juice with pH 6.8 and a rotation speed of 50 rpm.
% Release
-after 1 hour : 27.0
-after 2 hours: 44.4
-after 3 hours: 59.7 -after 4 hours: 73.0
-after 5 hovrs: 85.1
-after 6 hours: 94.5
EXAMPLE 2
A) Preparation of the mixture
Transfer 2550 g of sodium diclofenac into ' a laboratory blender and blend with 570 g of a solution of 15% hydroxypropylcellulose in 95% alcohol.
Granulate the paste obtained through a 1200 μm mesh screen and subsequently through 800 μm and 700 μm mesh screens .
The granules are dried at about 40 C for 12-15 hours in a circulating air oven and selected between 300 and 700 μm.
The following materials are transferred in a double cone shaped laboratory mixer: granulated sodium diclofenac (300-700 μm) 800. Og xanthan gum 1140. Og silicon dioxide 20. Og magnesium stearate 40. Og mix for about 15 minutes.
B) Preparation of the Minitablets
The mixture obtained from A) is compressed with a tabletting machine , model Ronchi AM13 equipped with punchers (diameter 2mm, bending radius 3mm) giving minitablets with an average weight of 7.7 mg and each containing 2.9 mg of diclofenac.
C) Preparation of the Final Pharmaceutical Form
Utilizing hard gelatin capsules, type Snap Fit size 1,35 of the small tablets produced in B were introduced into each capsule with a suitable capsule filling machine •
Each capsule contains 100 mg of sodium diclofenac.
D) Analysis
The minitablets were analysed with the rotating paddle mthod described in the current edition of the US Pharmacopoeia (USP) using 900 ml of artificial intestinal juice with pH 6.8 and a rotation speed of 50 rpm.
% Release -
-after 1 hour: 30.2
-after 2 hours: 52.9
-after 3 hours: 65.1
-after 4 hours: 72.6
-after 6 hours: 99.0
EXAMPLE 3
A) Preparation of the Mixture
Transfer the following raw materials, previously sieved through a 0.5 mm sieve, in a stainless steel laboratory cube mixer
granulate theophylline (200-400 μm) 108.7g xar.than gum 41.5g hydroxypropylmethylcellu.lose 44.5g silicone dioxide 0.9g magnesium stearate 1.4g Mix for about 15 minutes
B) Preparation of the Minitablets
The mixture obtained from A) is compressed with a compressing machine, model Ronchi AM13 equipped with punchers (diameter 2 mm,- bending radius 3 mm) giving minitabs with an average weight of 8.1 mg and each containing 4.4 mg of theophylline.
C) Preparation of the Final Pharmaceutical Form
Utilizing hard gelatin capsules, type Coni Snap Fit size 0 ,45 of the small tablets produced in B were introduced into each capsule with a suitable filling machine.
Each capsule contains 200 mg of theophylline.
D) Analysis
The minitablets were analyzed with the rotating paddle method described in the current edition of the US Pharmacopoeia (USP) using 900 ml of artificial intestinal juice with pH 7.5 and a rotation speed of 50 rpm.
% Release
-after 1 hour: 43.5
-after 2 hours: 68.9
-after 3 hours: 99.0
The minitablets were analyzed as described above using 900ml of artificial gastric juice with pH 1.2
% Release -after 1 hour: 53.9
-after 2 hours: 77.7
-after 4 hours: 100
Claims
1. A pharmaceutical dosage form comprising a hard gelatin capsule containing a multiplicity of minitablets providing prolonged and regular release of the active ingredient, said tablets comprising one or more active medicaments contained within a matrix which provides a sustained release effect, the matrix consisting essentially of xanthan gum or a mixture of xanthan gum and one or more natural or synthetic polymers, which hydrate and dissolve in water or gastric juices.
2. A pharmaceutical dosage form as claimed in Claim 1, wherein the matrix comprises at least 50% of xanthan gum.
3. A pharmaceutical dosage form as claimed in Claim 1 or Claim 2, wherein the matrix consists essentially of xanthan gum and one or both of hydroxypropylcellulose or hydroxypropylmethylcellulose .
4. A pharmaceutical dosage form as claimed in any one of the preceding Claims wherein the minitablets also contain conventional inert excipients.
5. A pharmaceutical dosage form as claimed in any one of the preceding claims wherein the active medicament is ibuprofen, theophylline or sodium diclofenac .
6. A pharmaceutcal dosage form as claimed in any one of the preceding Claims wherein the capsule contains from 30 - 50 minitablets.
7. A method for the preparation of a pharmaceutical dosage form which method comprises mixing an active medicament with xanthan gum or a mixture of xanthan gum and one or more natural or synthetic polymers, which hydrate and dissolve in water or gastro-intestinal juices, forming the mixture into minitablets, filling the minitablets into hard gelatin capsules so that each capsule contains a multiplicity of minitablets, the xanthan gum or xantham gum mixture providing a matrix from which in use the active medicament has a prolonged and regular release .
8. A method as claimed in Claim 7, wherein the dosage form is as claimed in any one of Claims 1 - 6.
9. A pharmaceutical dosage form as claimed in Claim 1, substantially as hereinbefore described in any one of Examples 1 - 3.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT02133890A IT1250483B (en) | 1990-08-30 | 1990-08-30 | MULTIPLE DIE DELAY SYSTEM |
| IT21338A/90 | 1990-08-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1992004013A1 true WO1992004013A1 (en) | 1992-03-19 |
Family
ID=11180325
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP1991/001562 WO1992004013A1 (en) | 1990-08-30 | 1991-08-15 | Multiparticulate sustained release matrix system |
Country Status (7)
| Country | Link |
|---|---|
| AU (1) | AU8395691A (en) |
| IE (1) | IE912885A1 (en) |
| IT (1) | IT1250483B (en) |
| NZ (1) | NZ239567A (en) |
| PT (1) | PT98791A (en) |
| WO (1) | WO1992004013A1 (en) |
| ZA (1) | ZA916518B (en) |
Cited By (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993018755A1 (en) * | 1992-03-25 | 1993-09-30 | Depomed Systems, Incorporated | Alkyl-substituted cellulose-based sustained-release oral drug dosage forms |
| DE4310963A1 (en) * | 1993-04-03 | 1994-10-06 | Knoll Ag | Extended-release tablet of beta-phenylpropiophenone derivatives |
| EP0804174A1 (en) * | 1993-07-21 | 1997-11-05 | The University of Kentucky Research Foundation | A multicompartment hard capsule with control release properties |
| US5948437A (en) * | 1996-05-23 | 1999-09-07 | Zeneca Limited | Pharmaceutical compositions using thiazepine |
| WO2003082804A1 (en) | 2002-03-28 | 2003-10-09 | Synthon B.V. | Venlafaxine besylate |
| EP1424069A2 (en) * | 1996-09-19 | 2004-06-02 | Depomed, Inc. | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
| EP1581160A2 (en) * | 2001-07-31 | 2005-10-05 | Capricorn Pharma, Inc. | Encapsulation products for controlled or extended release |
| NO20072938L (en) * | 2004-11-19 | 2007-08-20 | Smithkline Beecham Corp | Pharmaceutical product and process for its preparation. |
| EP2359814A1 (en) * | 2010-02-11 | 2011-08-24 | Laboratorios Liconsa, S.A. | Pharmaceutical mini-tablets for sustained release of flecainide acetate |
| US8333992B2 (en) | 2001-10-25 | 2012-12-18 | Depomed, Inc. | Gastric retained gabapentin dosage form |
| US8394409B2 (en) | 2004-07-01 | 2013-03-12 | Intellipharmaceutics Corp. | Controlled extended drug release technology |
| US8440232B2 (en) | 2001-10-25 | 2013-05-14 | Depomed, Inc. | Methods of treatment using a gastric retained gabapentin dosage |
| US8592481B2 (en) | 2005-12-29 | 2013-11-26 | Depomed, Inc. | Gastric retentive gabapentin dosage forms and methods for using same |
| US8603520B2 (en) | 2003-06-26 | 2013-12-10 | Intellipharmaceutics Corp. | Oral multi-functional pharmaceutical capsule preparations of proton pump inhibitors |
| US9078827B2 (en) | 2006-05-12 | 2015-07-14 | Isa Odidi | Pharmaceutical composition having reduced abuse potential |
| US9561188B2 (en) | 2006-04-03 | 2017-02-07 | Intellipharmaceutics Corporation | Controlled release delivery device comprising an organosol coat |
| US10064828B1 (en) | 2005-12-23 | 2018-09-04 | Intellipharmaceutics Corp. | Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems |
| US10624858B2 (en) | 2004-08-23 | 2020-04-21 | Intellipharmaceutics Corp | Controlled release composition using transition coating, and method of preparing same |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2176999A (en) * | 1985-06-22 | 1987-01-14 | Stanley Stewart Davis | Multiparticulate sustained release medicament |
| EP0234670B1 (en) * | 1986-01-18 | 1992-06-24 | The Boots Company PLC | Sustained-release pharmaceutical formulation containing xanthan gum |
-
1990
- 1990-08-30 IT IT02133890A patent/IT1250483B/en active IP Right Grant
-
1991
- 1991-08-14 IE IE288591A patent/IE912885A1/en unknown
- 1991-08-15 WO PCT/EP1991/001562 patent/WO1992004013A1/en unknown
- 1991-08-15 AU AU83956/91A patent/AU8395691A/en not_active Abandoned
- 1991-08-16 ZA ZA916518A patent/ZA916518B/en unknown
- 1991-08-28 PT PT98791A patent/PT98791A/en not_active Application Discontinuation
- 1991-08-28 NZ NZ239567A patent/NZ239567A/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2176999A (en) * | 1985-06-22 | 1987-01-14 | Stanley Stewart Davis | Multiparticulate sustained release medicament |
| EP0234670B1 (en) * | 1986-01-18 | 1992-06-24 | The Boots Company PLC | Sustained-release pharmaceutical formulation containing xanthan gum |
Cited By (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU668386B2 (en) * | 1992-03-25 | 1996-05-02 | Depomed Systems, Incorporated | Alkyl-substituted cellulose-based sustained-release oral drug dosage forms |
| WO1993018755A1 (en) * | 1992-03-25 | 1993-09-30 | Depomed Systems, Incorporated | Alkyl-substituted cellulose-based sustained-release oral drug dosage forms |
| CN1092957C (en) * | 1993-04-03 | 2002-10-23 | 克诺尔有限公司 | Retarded-action microtablet made of beta-phenylpropiophenone derivatives |
| DE4310963A1 (en) * | 1993-04-03 | 1994-10-06 | Knoll Ag | Extended-release tablet of beta-phenylpropiophenone derivatives |
| WO1994022434A1 (en) * | 1993-04-03 | 1994-10-13 | Knoll Aktiengesellschaft | RETARDED-ACTION MICROTABLET MADE OF β-PHENYLPROPIOPHENONE DERIVATIVES |
| EP0804174A1 (en) * | 1993-07-21 | 1997-11-05 | The University of Kentucky Research Foundation | A multicompartment hard capsule with control release properties |
| EP0804174A4 (en) * | 1993-07-21 | 1998-09-09 | Univ Kentucky Res Found | A multicompartment hard capsule with control release properties |
| US5948437A (en) * | 1996-05-23 | 1999-09-07 | Zeneca Limited | Pharmaceutical compositions using thiazepine |
| EP1424069A2 (en) * | 1996-09-19 | 2004-06-02 | Depomed, Inc. | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
| EP1424069A3 (en) * | 1996-09-19 | 2004-09-08 | Depomed, Inc. | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
| EP1581160A4 (en) * | 2001-07-31 | 2009-08-12 | Capricorn Pharma Inc | Encapsulation products for controlled or extended release |
| EP1581160A2 (en) * | 2001-07-31 | 2005-10-05 | Capricorn Pharma, Inc. | Encapsulation products for controlled or extended release |
| US8333991B2 (en) | 2001-10-25 | 2012-12-18 | Depomed, Inc. | Gastric retained gabapentin dosage form |
| US8333992B2 (en) | 2001-10-25 | 2012-12-18 | Depomed, Inc. | Gastric retained gabapentin dosage form |
| US8529955B2 (en) | 2001-10-25 | 2013-09-10 | Depomed, Inc. | Methods of treatment using a gastric retained gabapentin dosage |
| US8475813B2 (en) | 2001-10-25 | 2013-07-02 | Depomed, Inc. | Methods of treatment using a gastric retained gabapentin dosage |
| US8802157B2 (en) | 2001-10-25 | 2014-08-12 | Depomed, Inc. | Methods of treatment using a gastric retained gabapentin dosage form |
| US8440232B2 (en) | 2001-10-25 | 2013-05-14 | Depomed, Inc. | Methods of treatment using a gastric retained gabapentin dosage |
| US8580303B2 (en) | 2001-10-25 | 2013-11-12 | Depomed, Inc. | Gastric retained gabapentin dosage form |
| US8409613B2 (en) | 2001-10-25 | 2013-04-02 | Depomed, Inc. | Gastric retained gabapentin dosage form |
| WO2003082804A1 (en) | 2002-03-28 | 2003-10-09 | Synthon B.V. | Venlafaxine besylate |
| US9636306B2 (en) | 2003-06-26 | 2017-05-02 | Intellipharmaceutics Corp. | Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient |
| US8603520B2 (en) | 2003-06-26 | 2013-12-10 | Intellipharmaceutics Corp. | Oral multi-functional pharmaceutical capsule preparations of proton pump inhibitors |
| US8802139B2 (en) | 2003-06-26 | 2014-08-12 | Intellipharmaceutics Corp. | Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient |
| US8394409B2 (en) | 2004-07-01 | 2013-03-12 | Intellipharmaceutics Corp. | Controlled extended drug release technology |
| US10624858B2 (en) | 2004-08-23 | 2020-04-21 | Intellipharmaceutics Corp | Controlled release composition using transition coating, and method of preparing same |
| EP1830791A4 (en) * | 2004-11-19 | 2012-12-12 | Glaxosmithkline Llc | Pharmaceutical product |
| CN101102743A (en) * | 2004-11-19 | 2008-01-09 | 史密丝克莱恩比彻姆公司 | Pharmaceutical product |
| EP1830791A2 (en) * | 2004-11-19 | 2007-09-12 | Smithkline Beecham Corporation | Pharmaceutical product |
| NO341738B1 (en) * | 2004-11-19 | 2018-01-15 | Glaxosmithkline Llc | Pharmaceutical product and process for its preparation. |
| NO20072938L (en) * | 2004-11-19 | 2007-08-20 | Smithkline Beecham Corp | Pharmaceutical product and process for its preparation. |
| US10064828B1 (en) | 2005-12-23 | 2018-09-04 | Intellipharmaceutics Corp. | Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems |
| US8592481B2 (en) | 2005-12-29 | 2013-11-26 | Depomed, Inc. | Gastric retentive gabapentin dosage forms and methods for using same |
| US9561188B2 (en) | 2006-04-03 | 2017-02-07 | Intellipharmaceutics Corporation | Controlled release delivery device comprising an organosol coat |
| US9078827B2 (en) | 2006-05-12 | 2015-07-14 | Isa Odidi | Pharmaceutical composition having reduced abuse potential |
| US10960077B2 (en) | 2006-05-12 | 2021-03-30 | Intellipharmaceutics Corp. | Abuse and alcohol resistant drug composition |
| WO2011098194A3 (en) * | 2010-02-11 | 2012-01-26 | Laboratorios Liconsa, S. A. | Pharmaceutical mini-tablets for sustained release of flecainide acetate |
| EP2359814A1 (en) * | 2010-02-11 | 2011-08-24 | Laboratorios Liconsa, S.A. | Pharmaceutical mini-tablets for sustained release of flecainide acetate |
Also Published As
| Publication number | Publication date |
|---|---|
| PT98791A (en) | 1992-07-31 |
| NZ239567A (en) | 1992-06-25 |
| IT1250483B (en) | 1995-04-07 |
| IT9021338A1 (en) | 1992-02-29 |
| AU8395691A (en) | 1992-03-30 |
| IE912885A1 (en) | 1992-03-11 |
| ZA916518B (en) | 1992-05-27 |
| IT9021338A0 (en) | 1990-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2617109B2 (en) | Formulation of sustained release drug for oral administration | |
| EP0797435B1 (en) | Controlled release matrix for pharmaceuticals | |
| FI113336B (en) | Process for the preparation of tramadol salt containing drug with sustained release of active substance | |
| WO1992004013A1 (en) | Multiparticulate sustained release matrix system | |
| US4814179A (en) | Floating sustained release therapeutic compositions | |
| US7985421B2 (en) | Sustained release formulations of guaifenesin and additional drug ingredients | |
| JP3624123B2 (en) | Pharmaceutical controlled release matrix | |
| CN102105136B (en) | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic | |
| US20170007543A1 (en) | Sustained release of guaifenesin | |
| JPH01250314A (en) | Gradual release agent | |
| AU2001260212C1 (en) | Composition | |
| JPH059413B2 (en) | ||
| JPH0830007B2 (en) | Sustained release capsule | |
| JP2003531849A (en) | Guaifenesin sustained-release preparations and tablets | |
| US4814178A (en) | Floating sustained release therapeutic compositions | |
| US7985420B2 (en) | Sustained release of guaifenesin combination drugs | |
| CN1538837A (en) | Swallow tablet comprising paracetamol | |
| EP0198769A2 (en) | Floating sustained release therapeutic compositions | |
| GB2176999A (en) | Multiparticulate sustained release medicament | |
| JP2535141B2 (en) | Fumaric acid-containing sustained-release preparation | |
| JP2638604B2 (en) | Sustained release formulation | |
| EP0196002B1 (en) | Tablet composition for drug combinations | |
| JPH1081634A (en) | Base controlled in dissolution time | |
| CA1269043A (en) | Floating sustained release therapeutic compositions | |
| JPH01151513A (en) | Sustained release pharmaceutical and production thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP KR SU US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE |
|
| NENP | Non-entry into the national phase |
Ref country code: CA |